Xtant Medical Holdings, Inc. Announces Board Changes
August 24, 2022 at 08:16 am
Share
Xtant Medical Holdings, Inc. announced that in connection with the Private Placement, the Board of Directors of the Company increased the size of the Board from six directors to seven directors and elected Stavros Vizirgianakis to the Board to fill the vacancy created by such increase, in each case effective upon completion of the First Closing. Additionally, the Board elected Vizirgianakis as Chairman of the Board, effective upon completion of the First Closing, to replace Jeffrey Peters, who is currently serving as Chairman of the Board and intends not to stand for re-election at the Company's next annual meeting of stockholders, which is anticipated to be held during the fourth quarter of 2022.
Xtant Medical Holdings, Inc. is a global medical technology company. The Company is focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant fixation systems to facilitate spinal fusion in complex spine, deformity, and degenerative procedures. Its products are used by orthopedic spine surgeons and neurosurgeons to treat a variety of spinal disorders in the cervical, thoracolumbar, and interbody spine. Its biomaterial products include OsteoSponge, OsteoSponge SC, OsteoSelect DBM putty, OsteoSelect Plus DBM putty, OsteoWrap, and its line of 3Demin products, as well as other allografts. It offers a comprehensive line of products that are used to treat a variety of spinal and sacroiliac conditions, including trauma, degeneration, deformity and tumor. Its key spinal implant product lines include Cervical Products, Thoracolumbar Products, Sacroiliac Joint Products, Interbody Products and Interlaminar Stabilization Products.
XTANT MEDICAL HOLDINGS, INC. 
